The Lancet
Oncology by Mario Giuliano, Francesco Schettini, Carla Rognoni,
Manuela Milani, Guy Jerusalem, Thomas Bachelot, Michelino De Laurentiis,
Guglielmo Thomas, Pietro De Placido, Grazia Arpino, Sabino De Placido, Massimo
Cristofanilli, Antonio Giordano, Fabio Puglisi, Barbara Pistilli, Aleix Prat,
Lucia Del Mastro, Sergio Venturini, Daniele Generali
ARTICLES| VOLUME
20, ISSUE 10, P1360-1369, OCTOBER 01, 2019
In the first-line or
second-line setting, CDK4/6 inhibitors plus hormone therapies are better than
standard hormone therapies in terms of progression-free survival. Moreover, no
chemotherapy regimen with or without targeted therapy is significantly better
than CDK4/6 inhibitors plus hormone therapies in terms of progression-free
survival. Our data support treatment guideline recommendations involving the
new combinations of hormone therapies plus targeted therapies as first-line or
second-line treatments, or in both settings, in women with
hormone-receptor-positive, HER2-negative metastatic breast cancer.
